

The background of the slide is a close-up, artistic photograph of a laboratory setting. It features several glass pipettes in the upper right, angled downwards towards a multi-well microplate. The microplate is filled with a vibrant pink or magenta liquid. The entire scene is bathed in a cool blue light, creating a high-tech, scientific atmosphere. The focus is sharp on the pipettes and the liquid in the wells, with a slight blur in the background.

skan

SKAN Group Investor Presentation

June 2026

THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL.

This presentation (the "Presentation"), contains information regarding SKAN Group AG (the "Company") and each of its subsidiaries and affiliates (the "Group"). The information and opinions contained in this Presentation do not purport to be comprehensive and are provided as at the date of this Presentation or as of the date specified herein. Certain financial information (including percentages) in this Presentation may have been rounded according to commercial standards. As a result, the aggregate amounts may not correspond in all cases to the aggregated amounts of the underlying (unrounded) figures appearing elsewhere in this Presentation.

The financial information presented herein has been prepared in accordance with Swiss GAAP FER. Certain financial data included in this Presentation consists of non-Swiss GAAP FER financial measures. These non-Swiss GAAP FER financial measures may not be comparable to similarly titled measures presented by other companies, nor should they be construed as an alternative to other financial measures determined in accordance with Swiss GAAP FER. In addition, certain financial information contained herein has not been audited, confirmed or otherwise covered by a report by independent accountants and, as such, actual data could vary, possibly significantly, from the data set forth herein. None of the Company, the Group, and any other person is under any obligation to update or keep current the information contained in this Presentation or to correct any inaccuracies which may become apparent, and any opinions expressed herein are subject to change without notice.

Statements made in this Presentation may include forward-looking statements. These statements may be identified by the fact that they use words such as "anticipate", "estimate", "should", "expect", "guidance", "project", "intend", "plan", "believe", "will", "could" and/or other words and terms of similar meaning in connection with, among other things, any discussion of results of operations, financial condition, liquidity, prospects, growth, strategies or developments in the industry in which we operate. Such statements are based on management's current intentions, expectations or beliefs and involve inherent risks, assumptions and uncertainties, including factors that could delay, divert or change any of them. Forward-looking statements contained in this Presentation regarding trends or current activities should not be taken as a representation that such trends or activities will continue in the future. Actual outcomes, results and other future events may differ materially from those expressed or implied by the statements contained herein. Such differences may adversely affect the outcome and financial effects of the plans and events described herein and may result from, among other things, changes in economic, business, competitive, technological, strategic or regulatory factors and other factors affecting the business and operations of the company. Neither the Company nor any of their subsidiaries or affiliates are under any obligation, and each such entity expressly disclaims any such obligation, to update, revise or amend any forward-looking statements, whether as a result of new information, future events or otherwise.

Further, this Presentation may include market share and industry data obtained by the Company from industry publications and market surveys. The Company may not have access to the facts and assumptions underlying the numerical data, market data and other information extracted from public sources and neither the Company, the Group, nor any of their respective directors, officers , employees, shareholders, affiliates, agents and advisers are able to verify such information, and assume no responsibility for the correctness of any such information.

This Presentation does not constitute or form part of, and should not be construed as, an offer or invitation or inducement to subscribe for or otherwise acquire, any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Group, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This Presentation does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). Neither the Company nor any other member of the Group has registered or intends to register any securities under the Securities Act or the securities laws of any state or other jurisdiction of the United States.

THIS PRESENTATION IS NOT AN INVITATION TO PURCHASE SECURITIES OF THE COMPANY OR THE GROUP.

Key challenge for (bio-)pharmaceutical products

Key challenge	Products	In particular true for
Medical safety Medication safety is key and (cross-) contamination unacceptable Key contamination sources: → Air particles → Input: Raw materials, containers, closures → Personnel 	Injectables → Cancer drugs: Antibody Drug Conjugates (ADC), Cytotoxics → Cell & gene therapy: Advanced Therapy Medicinal Products (ATMPs) → Hormones: GLP-1, Insulin → Medical drugs: Thrombosis, EPO, blood plasma products, botox, etc. → Vaccines: Flu, etc. Infection risk as application bypasses natural defenses of the human body 	High-value biopharma drugs → Risk of significant economic losses if high-value biopharma drugs get contaminated → Risk of cross-contamination increases with small batch size of fast-growing personalized medicine

Isolators are mission critical for aseptic production processes

Solution: Medication sterility

TRADITIONAL PHARMA

Pharma products mainly chemical based



CLEANROOM

- + Filling / closing in cleanroom with terminal sterilization
- Inappropriate for complex biopharmaceuticals

Cleanroom environment

Terminal sterilisation

Raw materials procurement

Formulation

Fill-finish

Quality control

Packaging & shipping

↑ Sterilisation

Aseptic processing

BIOPHARMA OF TODAY AND TOMORROW

New products mainly biotech-based (sensitive to heat and pressure)



ISOLATORS

- + Filling/closing under aseptic conditions eliminating effectively all contamination risk
- + Reduced cleanroom footprint and running costs and environmental-friendly
- + Complex process results in high market entry barriers




SAL 10^{-3}
Probability of 1 in 1,000 of finding a non sterile unit



SAL 10^{-6}
Probability of 1 in 1,000,000 of finding a non sterile unit

Longstanding heritage in aseptic manufacturing equipment and processes




Technological edge and innovation

Fabrication know-how



Electron beam transfer



Filling technology



HVAC engineering
& air flow modelling



GMP documentation &
qualification of equipment



Automation &
digitalization expertise



Chemical know-how on cleaning
validation



Microbiological & H₂O₂ know-how
on surface decontamination



Decontamination cycle down to 3
minutes

- **Technology leadership and foresight** allows SKAN to be the market defining player
- **Continuous contribution to new guidelines & regulations** through industry standards setting organizations (ISPE, PDA, ISO)
- **Pure-play business model** enables an undiluted focus of resources to drive innovation
- **Approx. 1750 employees, of which more than 50% with academic background** such as scientists and engineers ensure seamless innovation and production

Structural growth drivers support SKAN's long-term expansion



Growth drivers for the biopharmaceutical market

Demographic trend and lifestyle promote chronic diseases

Development process of new biotech drugs speeding up

Double digit growth of underlying biologics market

Global biologics market size, 2018-2030 (US\$M)



The demand for injectable drugs will continue to grow structurally

Growth drivers for isolators in fill finish

Complex molecules are difficult and expensive to produce

- Injectable drugs need to be sterile when administered
- Some molecules are harmful if exposed to manufacturing and health care personnel

Containment during production is key for sterility and protection

- Sensitive in production
- Cannot be terminally sterilized
- Are typically of high value
- Dosing is key
- Injectable dosage form

Isolator technology provides highest safety and quality advantages

- Highly regulated (GMP)
- Aseptic environment
- Adaptive to sensitive drugs
- Operator and cross contamination protection
- Lower running costs (energy, quality)



Demand for isolators will grow with the industry and continue to replace older technologies

SKAN's leadership position is underpinned by high entry barriers and compelling value proposition

Entry barriers	SKAN's value proposition	Key purchasing criteria	Selected customers
 Technological edge	 Mastery of difficult to replicate know-how on highest-performance isolators	Product quality / reliability	abbvie Baxter
 Stringent regulatory environment	 Process warranty regarding all regulatory (e.g. FDA, EMA, Swissmedic) required qualifications & timeline	Brand reputation	GILEAD 
 Mission criticality of aseptic processes	 Swiss brand, engineering & reputation provide trust in isolator safety	Validation process support	Johnson & Johnson Lilly
 Lock-in effect	 Large installed base of isolators and leading global services incl. tech transfer & consumables across product lifecycle	Aftersales service / proximity	Lonza 
		Relationship / track record	moderna [™] 
		Delivery time / reliability	NOVARTIS 
		Customisation capabilities	 Pfizer
		Innovation and R&D capabilities	 
		Breadth of product offering	
		Price / TCO	

Decreasing relative importance

Comprehensive portfolio for aseptic manufacturing processes

Equipment & Solutions

65% of sales

Services & Consumables

35% of sales

Pure Solutions

Business contrib.

Trading

Trading of Laboratory/cleanroom equipment, mostly in Switzerland

- Workbenches
- Laminar flows
- Fume cupboards



Consumables

- Personal protective equipment

Services

- Consulting
- Commissioning
- Maintenance

Isolator Solutions

Business contrib.

Customized Solutions

- Customer-specific isolator solutions for aseptic manufacturing and filling
- Process warranty incl. complete GMP compliance



Modular Solutions

- Isolators with up to 80% standardization, equipped flexibly with process tools
- Close collaboration with process tool partners



Consumables

- Biological indicators
- Spares (gloves, filters, etc.)
- ABC Transfer Betabags



Services

- Life cycle support
- GMP requalification
- Performance studies
- Digital integration into MES⁽¹⁾ and ERP systems
- Retrofit

Integrated Process Solutions

Business contrib.

Aseptic Technologies (AT)

- Automated closed-vial filling equipment for small/medium-batch integrated into isolator
- ABC Transfer port/container as rapid transfer system



Process Automation

- Global process solution providing automated (robotic) process handling fully integrated within the isolator



Consumables

- Closed vials
- Connectors
- Filling kits



Services

- Rent a machine
- Life cycle support

Consumables

- Refer to Isolator Solutions consumables


Services

- Refer to Isolator Solutions services

Excellent track-record with consistent above-market growth and increasing profitability


Net sales & order intake

(CHFm)



EBITDA

EBITDA (CHFm) and EBITDA margin (%)



Sustained above-market growth and margin improvement, with momentum continuing beyond an exceptional 2025.



Strong revenue visibility based on order backlog of CHF 346.1m as of end of 2025



Innovation as the foundation of our technology leadership and growth engine: continuous investment of 7 – 8 % of net sales.



Solid ROCE⁽¹⁾ despite significant growth investments



Strong balance sheet & financing structure providing full flexibility for future growth




Structural negative working capital

SKAN Group's growth strategy



Shift toward injectable biotech drugs continues and drives need for aseptic process solutions



SKAN's investment highlights

1 | **Market leader globally** for high-end aseptic process solutions



2 | **Technology & innovation leadership**



3 | Strategically positioned in a **highly dynamic & rapidly growing niche market**



4 | **Significant barriers to entry**



5 | **Trusted, long-term partner** to a large, diversified customer base

6 | **Experienced & entrepreneurial management** with proven track record

7 | **Excellent financial profile** with demonstrated above-market growth

8 | **Clear strategy** with multiple avenues for growth and margin improvement



The image shows a bright, modern office lobby. In the foreground, a curved white reception desk features the slogan "Together always one step ahead" in white text. Behind the desk, a large glass wall provides a view into an office area with desks and computers. To the right, a prominent white sculptural staircase with a wooden handrail and steps leads to an upper level. The ceiling is white with large, organic-shaped cutouts that reveal a brown interior. The floor is a smooth, light grey. In the background, there is a lounge area with a blue sofa, a yellow armchair, and potted plants. The overall design is clean, minimalist, and architecturally striking.

Together always one step ahead

skan